IL92622A - Pharmaceutical preparations containing enzymatic conversion inhibitors of protoporphyrinogen to protoporphyrin XI for use in the treatment or detection of tumors - Google Patents

Pharmaceutical preparations containing enzymatic conversion inhibitors of protoporphyrinogen to protoporphyrin XI for use in the treatment or detection of tumors

Info

Publication number
IL92622A
IL92622A IL9262289A IL9262289A IL92622A IL 92622 A IL92622 A IL 92622A IL 9262289 A IL9262289 A IL 9262289A IL 9262289 A IL9262289 A IL 9262289A IL 92622 A IL92622 A IL 92622A
Authority
IL
Israel
Prior art keywords
aryl
compound
protoporphyrinogen
protoporphyrin
composition
Prior art date
Application number
IL9262289A
Other languages
English (en)
Hebrew (he)
Other versions
IL92622A0 (en
Inventor
Blaik Phillip Halling
Debra Ann Witkowski
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of IL92622A0 publication Critical patent/IL92622A0/xx
Publication of IL92622A publication Critical patent/IL92622A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL9262289A 1988-12-12 1989-12-10 Pharmaceutical preparations containing enzymatic conversion inhibitors of protoporphyrinogen to protoporphyrin XI for use in the treatment or detection of tumors IL92622A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28515188A 1988-12-12 1988-12-12
US33500789A 1989-04-07 1989-04-07
US35133189A 1989-05-03 1989-05-03

Publications (2)

Publication Number Publication Date
IL92622A0 IL92622A0 (en) 1990-08-31
IL92622A true IL92622A (en) 1996-05-14

Family

ID=27403508

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9262289A IL92622A (en) 1988-12-12 1989-12-10 Pharmaceutical preparations containing enzymatic conversion inhibitors of protoporphyrinogen to protoporphyrin XI for use in the treatment or detection of tumors

Country Status (28)

Country Link
EP (1) EP0447491B1 (xx)
JP (1) JP2545000B2 (xx)
KR (1) KR930003116B1 (xx)
AR (1) AR243605A1 (xx)
AT (1) AT400520B (xx)
AU (1) AU633537B2 (xx)
BR (1) BR8907817A (xx)
CA (1) CA2004979A1 (xx)
CH (1) CH681779A5 (xx)
DE (2) DE3991484T (xx)
DK (1) DK110791A (xx)
EG (1) EG18822A (xx)
ES (1) ES2051675T3 (xx)
FI (1) FI912784A0 (xx)
GB (1) GB2247404B (xx)
GR (1) GR1000609B (xx)
HU (1) HUT58202A (xx)
IE (1) IE62621B1 (xx)
IL (1) IL92622A (xx)
LU (1) LU87949A1 (xx)
LV (1) LV10303B (xx)
MC (1) MC2171A1 (xx)
NO (1) NO912228L (xx)
NZ (1) NZ231658A (xx)
OA (1) OA09362A (xx)
PT (1) PT92546B (xx)
SE (1) SE505938C2 (xx)
WO (1) WO1990006748A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298502A (en) * 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
US5132101A (en) * 1990-05-04 1992-07-21 Cytopharm, Inc. Acetylene-cumulene porphycene compounds for photodynamic therapy
US5244671A (en) * 1991-01-29 1993-09-14 Cytopharm, Inc. Derivatives of porphycene for photodynamic therapy of cancer
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
GB9318841D0 (en) * 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
US5939602A (en) * 1995-06-06 1999-08-17 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
US6023012A (en) * 1996-02-28 2000-02-08 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase
US5767373A (en) 1994-06-16 1998-06-16 Novartis Finance Corporation Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
US6084155A (en) 1995-06-06 2000-07-04 Novartis Ag Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes
WO1997032011A1 (en) * 1996-02-28 1997-09-04 Novartis Ag Dna molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
JPH10330359A (ja) * 1997-03-31 1998-12-15 Nippon Bayeragrochem Kk フエニルアセチレン誘導体及び除草剤
DE102005017152B4 (de) * 2005-04-13 2007-02-08 Lindauer Dornier Gmbh Verfahren zum Trocknen von vorzugsweise plattenförmigen Produkten und Durchlauftrockner in Mehretagenbauweise
PL2443102T3 (pl) 2009-06-19 2013-09-30 Basf Se Benzoksazynonowe środki chwastobójcze
BR112012009987A2 (pt) * 2009-11-02 2015-09-29 Basf Se ''tetraidroftalimidas de fórmula ia ,processo para preparação de composições herbicidas ativas e método para controlar vegetações indesejadas''
CN103221409B (zh) * 2010-10-01 2016-03-09 巴斯夫欧洲公司 除草的苯并*嗪酮类
AU2011344311B2 (en) 2010-12-15 2015-05-14 Basf Se Herbicidal compositions
CN102875569A (zh) * 2012-09-27 2013-01-16 南开大学 具有除草活性和抗肝癌活性的异噁唑并嘧啶酮(或三嗪酮)类化合物
US11185075B2 (en) * 2016-12-16 2021-11-30 Basf Se Herbicidal phenyltriazolinones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393071A (en) * 1975-03-17 1983-07-12 Naoharu Fujii Method of treating gastric, mammary, lung and uterus tumors
US4404019A (en) * 1980-12-24 1983-09-13 Sumitomo Chemical Company, Limited 3-Chloro-1-phenyl-1,2,4-triazolin-5-ones and their use as herbicides
CH651029A5 (de) * 1980-12-25 1985-08-30 Nihon Nohyaku Co Ltd Triazolin-derivate, verfahren zu ihrer herstellung und sie enthaltende herbizide mittel.
JPS60190711A (ja) * 1984-03-09 1985-09-28 Tokyo Tanabe Co Ltd プロトポルフイリン類注射用製剤
US4755217A (en) * 1987-01-15 1988-07-05 Fmc Corporation Triazinedione herbicides
US4761174A (en) * 1987-04-14 1988-08-02 Fmc Corporation Triazolin-5-one herbicides

Also Published As

Publication number Publication date
HUT58202A (en) 1992-02-28
ES2051675T1 (es) 1994-07-01
KR910700046A (ko) 1991-03-13
LV10303B (en) 1995-08-20
NO912228D0 (no) 1991-06-11
EG18822A (en) 1994-09-29
GB2247404B (en) 1993-03-03
GB9110472D0 (en) 1991-11-27
SE9101807D0 (sv) 1991-06-12
JP2545000B2 (ja) 1996-10-16
GR1000609B (el) 1992-08-31
DK110791D0 (da) 1991-06-11
LV10303A (lv) 1994-10-20
OA09362A (en) 1992-09-15
NZ231658A (en) 1992-05-26
LU87949A1 (fr) 1991-12-16
AT400520B (de) 1996-01-25
SE505938C2 (sv) 1997-10-27
ES2051675T3 (es) 1994-11-01
EP0447491A1 (en) 1991-09-25
ATA903489A (de) 1995-06-15
PT92546A (pt) 1990-06-29
JPH04501420A (ja) 1992-03-12
IE893925L (en) 1990-06-12
EP0447491B1 (en) 1993-08-11
WO1990006748A2 (en) 1990-06-28
CA2004979A1 (en) 1990-06-12
IL92622A0 (en) 1990-08-31
GB2247404A (en) 1992-03-04
KR930003116B1 (ko) 1993-04-19
CH681779A5 (xx) 1993-05-28
FI912784A0 (fi) 1991-06-10
DE3991484C2 (de) 1995-02-23
BR8907817A (pt) 1991-10-22
SE9101807L (sv) 1991-06-12
PT92546B (pt) 1995-09-12
AR243605A1 (es) 1993-08-31
WO1990006748A3 (en) 1990-10-04
DK110791A (da) 1991-08-12
AU633537B2 (en) 1993-02-04
MC2171A1 (fr) 1992-05-22
DE3991484T (xx) 1991-11-21
AU4822290A (en) 1990-07-10
NO912228L (no) 1991-06-11
IE62621B1 (en) 1995-02-22
GR890100817A (en) 1991-03-15

Similar Documents

Publication Publication Date Title
US5407808A (en) Method and composition for photodynamic treatment and detection of tumors
AU633537B2 (en) Use of certain herbicides in cancer treatment and production of protoporphyrin ix
US5298502A (en) Method and composition for photodynamic treatment and detection of tumors
SHUKLA et al. Glutathione peroxidase and catalase in liver, kidney, testis and brain regions of rats following cadmium exposure and subsequent withdrawal
US4898878A (en) Antioxidant thiohistidine compounds
Becker et al. [15] 1, 3-Bis (2-chloroethyl)-1-nitrosourea as Thiol-carbamoylating agent in biological Systems
Gibson et al. Relationship of δ-aminolevulinic acid-induced protoporphyrin IX levels to mitochondrial content in neoplastic cells in vitro
Santamaría et al. Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems
Siemann et al. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy
Subash et al. Effect of morin on the levels of circulatory liver markers and redox status in experimental chronic hyperammonaemic rats
US5602278A (en) N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells
WO1991019418A1 (en) Treatment of disease
Thakar et al. Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions
Mukhopadhyay et al. Vitamin D3 as a modulator of cellular antioxidant defence in murine lymphoma
RU2074719C1 (ru) Способ разрушения опухолевых клеток млекопитающих и фармацевтическая композиция для разрушения опухолевых клеток млекопитающих
Camadro et al. Kinetic properties of the membrane-bound human liver mitochondrial protoporphyrinogen oxidase
Labbe et al. Clinical-Biochemical Interpretations of Erythrocyte Protoporphyrin1
HRP930762A2 (en) Preparation and use of porphyrin
Aneja et al. Modulatory influence of tin-protoporphyrin on gossypol-induced alterations of heme oxygenase activity in male wistar rats
LT3997B (en) Process for preparing protoporphyrins and use thereof
Ziman et al. The effect of fluroxene [(2, 2, 2-trifluoroethoxy) ethane] on haem biosynthesis and degradation
Varior Biochemical and Histopathological effects of aflatoxin on Oreochromis mossambicus (Peters)
Chong Alterations in calcium homeostasis as a possible cause of Ochratoxin A nephrotoxicity
Suchithra et al. Biochemical and Histopathological Effects of Aflatoxin on Oreochromis mossambicus (Peters)
Blekkenhorst, GH, Eales, L. & Pimstone Activation of uroporphyrinogen decarboxylase by ferrous iron in porphyria cutanea tarda

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH Patent void